Trials
1 active
3 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Down Syndrome (Trisomy 21)
- Main trialPhase 2
- “The goal of this clinical trial is to identify if AEF0217 show an improvement in adaptive behaviors (daily life activities) in adults and older adolescents with Down Syndrome. It will also learn about the safety of AEF0217. The main questions it aims to answer are: * Does AEF0217 improve the daily life activities of the participants after being administered daily for 24 weeks ? * Does AEF0217 improve fluid cognitive function (cognitive abilities that do not depend on prior knowledge) and the crystallised one (knowledge acquired through one's culture, including verbal ability and social…”In the company’s words, NCT07334912 on ClinicalTrials.gov
Other drugs for Down Syndrome (Trisomy 21)
- ACI-24.060AC Immune SA · Phase 1/2
- MivelsiranAlnylam · Phase 2
Coming up1
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Dec 2027 | AEF0217 in Participants With Down Syndrome | |
| Phase 1/2Completed | 7 Oct 2024 | Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome | |
| Phase 1Completed | 28 Jun 2022 | AEF0217 First-in-Human Phase I Study in 3 Parts (Single and Multiple Ascending Doses, and Food Effect) in Healthy Subjects. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026